Abstract
Recent progress in molecular biology has provided application of gene transfer methods in arthritis. Two clinical trails using ex vivo retrovirus mediated delivery of interleukin -1 receptor antagonist gene for rheumatoid arthritis has begun in USA and Germany. However, there are still many issues to be elucidated; one is the development of gene delivery system, and the other is the selection of therapeutic gene. Arthritis is nonlethal disease, and safety is one of the important issues. Currently viral mediated vectors are major even in clinical trials however, non viral efficient gene transfer system should be developed in future. Recently the application of DNA technologies, such as antisense oligonucleotide (ODN) strategies to regulate the transcription of disease-related genes in vivo, has significant therapeutic potential. Transfection of cis-element double-stranded oligonucleotides (decoy ODN) for nuclear factor kB binding site has been reported as a new powerful tool in arthritis. The concept of regulation the disease related gene expression at the level of transcriptional factor may be more therapeutic effects compared with monotherapy in arthritis.
Keywords: rheumatoid arthritis, osteoarthritis, gene therapy, vector system, decoy deoxoligonucleotide, transcriptional factor, nuclear factor, joint destruction
Current Drug Targets
Title: Gene Therapy for Arthritis
Volume: 4 Issue: 8
Author(s): Tetsuya Tomita, Hideo Hashimoto and Hideki Yoshikawa
Affiliation:
Keywords: rheumatoid arthritis, osteoarthritis, gene therapy, vector system, decoy deoxoligonucleotide, transcriptional factor, nuclear factor, joint destruction
Abstract: Recent progress in molecular biology has provided application of gene transfer methods in arthritis. Two clinical trails using ex vivo retrovirus mediated delivery of interleukin -1 receptor antagonist gene for rheumatoid arthritis has begun in USA and Germany. However, there are still many issues to be elucidated; one is the development of gene delivery system, and the other is the selection of therapeutic gene. Arthritis is nonlethal disease, and safety is one of the important issues. Currently viral mediated vectors are major even in clinical trials however, non viral efficient gene transfer system should be developed in future. Recently the application of DNA technologies, such as antisense oligonucleotide (ODN) strategies to regulate the transcription of disease-related genes in vivo, has significant therapeutic potential. Transfection of cis-element double-stranded oligonucleotides (decoy ODN) for nuclear factor kB binding site has been reported as a new powerful tool in arthritis. The concept of regulation the disease related gene expression at the level of transcriptional factor may be more therapeutic effects compared with monotherapy in arthritis.
Export Options
About this article
Cite this article as:
Tomita Tetsuya, Hashimoto Hideo and Yoshikawa Hideki, Gene Therapy for Arthritis, Current Drug Targets 2003; 4 (8) . https://dx.doi.org/10.2174/1389450033490777
DOI https://dx.doi.org/10.2174/1389450033490777 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of TNF and Its Family Members in Inflammation and Cancer: Lessons from Gene Deletion
Current Drug Targets - Inflammation & Allergy Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry A Point of View: The Need to Identify an Antigen in Psyconeuroimmunological Disorders
Current Pharmaceutical Design Controlled Release Gel Encompassing Curcumin Microspheres and Diclofenac Diethylamine for Feat Against Arthritis Inflammation
Current Rheumatology Reviews The Clinical Potential of Worms and their Products in Treating Inflammatory Diseases
Current Immunology Reviews (Discontinued) Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews Metallic Nanopopcorns: A New Multimodal Approach for Theranostics
Current Nanoscience Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Current Pharmaceutical Design IL-22 and Its Receptors, New Players in the Inflammatory Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry A Review on Rheumatoid Arthritis Interventions and Current Developments
Current Drug Targets CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot-Topic: Molecular Mechanisms in Rheumatic Diseases:Rationale for Novel Drug Development (Guest Editor: Charles J. Malemud)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Iontophoretic Mediated Intraarticular Delivery of Deformable Liposomes of Diclofenac Sodium
Current Drug Delivery Epidemiology of Psoriasis
Current Drug Targets - Inflammation & Allergy Synthesis and Immunomodulation of Human Lymphocyte Proliferation and Cytokine (Interferon-γ) Production of Four Novel Leflunomide Analogues
Medicinal Chemistry Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry Anti-inflammatory Potential of GSK-3 Inhibitors
Current Drug Targets